Why the study?
Do truncated dominant-negative tie2 and VEGFR-2 mutants reduce tumor growth in murine breast cancer models?
Do truncated dominant-negative tie2 and VEGFR-2 mutants reduce tumor growth in murine breast cancer models?
Tumor angiogenesis depends on VEGFR-2, but tie2-dependent pathways also exist and vary between tumor types, suggesting the need to analyze prevailing pathways before applying angiogenesis inhibitors.
No takes yet. Share an insight, caveat, or question.
Truncated tie2/VEGFR-2 mutants variably inhibit murine breast tumor growth; leaves open tumor-type-specific pathway targeting before human trials.
Stratmann et al. (2001) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: